ZTS Q2 2025 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena

ZTSZoetis Inc.

$54B

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.5B+4.2% YoY

Gross Profit

$1.8B72.3% margin

Operating Income

$989M40.2% margin

Net Income

$718M29.2% margin

EPS (Diluted)

$1.61

QoQ Revenue Growth

+10.8%

Cash Flow

Operating Cash Flow

$486M

Free Cash Flow

$308M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$14.5B

Total Liabilities

$9.5B

Stockholders' Equity

$5.0B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.4B	+4.2%
Gross Profit	$1.8B	$1.7B	+7.2%
Operating Income	$989M	$906M	+9.2%
Net Income	$718M	$624M	+15.1%

Revenue Segments

Dogs and Cats

$1.7B71%

Cattle

$320M13%

Swine

$119M5%

Poultry

$103M4%

Fish

$74M3%

Horses

$72M3%

Geographic Segments

United States Segment

$1.4B56%

International Segment

$1.1B44%